Moderna retreats from 52-week high, wiping out $10 bln in value

** Shares of Moderna MRNA.O fall 11.6% to $209.16, snapping a three-day winning streak and worst performer on the Nasdaq 100 .NDX

** Stock on track for its biggest one-day drop since Aug 20, shedding $10 billion in market value if losses hold

** Pullback follows a 52-week high of $242.29 on Thursday and a gain of about 20% over the previous three sessions

** Shares are still up more than 50% over the past month and nearly tenfold from their 52-week low of $22.28 in November

** Rally has been driven by the late-stage cancer vaccine trial data developed with Merck MRK.N

** Detailed data from the Moderna-Merck cancer vaccine trial is due at the ESMO Congress on October 24

** Earlier this month, Moderna joined the Nasdaq 100 index to replace Warner Bros Discovery

** 6 of 25 brokerages rate Moderna's stock "buy" or higher, 15 rate it "hold" and four rate it "sell" or lower; their median price target is $130 - LSEG

** Including session's move, MRNA up more than sevenfold YTD